[go: up one dir, main page]

WO2007002830A3 - Diagnosis of and protection from hyperinsulinemia and type ii diabetes - Google Patents

Diagnosis of and protection from hyperinsulinemia and type ii diabetes Download PDF

Info

Publication number
WO2007002830A3
WO2007002830A3 PCT/US2006/025373 US2006025373W WO2007002830A3 WO 2007002830 A3 WO2007002830 A3 WO 2007002830A3 US 2006025373 W US2006025373 W US 2006025373W WO 2007002830 A3 WO2007002830 A3 WO 2007002830A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
diabetes
hyperinsulinemia
diagnosis
protection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/025373
Other languages
French (fr)
Other versions
WO2007002830A2 (en
Inventor
John J Kopchick
Edward List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University filed Critical Ohio University
Publication of WO2007002830A2 publication Critical patent/WO2007002830A2/en
Anticipated expiration legal-status Critical
Publication of WO2007002830A3 publication Critical patent/WO2007002830A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Mouse proteins differentially expressed in skin, in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic white adipose tissue have been identified, as have corresponding human proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.
PCT/US2006/025373 2005-06-29 2006-06-29 Diagnosis of and protection from hyperinsulinemia and type ii diabetes Ceased WO2007002830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69480005P 2005-06-29 2005-06-29
US60/694,800 2005-06-29

Publications (2)

Publication Number Publication Date
WO2007002830A2 WO2007002830A2 (en) 2007-01-04
WO2007002830A3 true WO2007002830A3 (en) 2008-07-31

Family

ID=37596045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025373 Ceased WO2007002830A2 (en) 2005-06-29 2006-06-29 Diagnosis of and protection from hyperinsulinemia and type ii diabetes

Country Status (1)

Country Link
WO (1) WO2007002830A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120962A2 (en) * 2008-03-28 2009-10-01 Ohio University Protein isoforms for diagnosis
CN114609228B (en) * 2022-03-08 2024-11-19 西湖大学 A high-throughput protein extraction method suitable for tongue coating samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143491A (en) * 1996-11-12 2000-11-07 Millennium Pharmaceuticals, Inc. Therapeutic compositions and methods and diagnostic assays for type II diabetes involving HNF-1
US20030100014A1 (en) * 2001-11-23 2003-05-29 George Jackowski Apolipoprotein biopolymer markers predictive of type II diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143491A (en) * 1996-11-12 2000-11-07 Millennium Pharmaceuticals, Inc. Therapeutic compositions and methods and diagnostic assays for type II diabetes involving HNF-1
US20030100014A1 (en) * 2001-11-23 2003-05-29 George Jackowski Apolipoprotein biopolymer markers predictive of type II diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HITTEL ET AL.: "Proteome Analysis of Skeletal Muscle From Obese and Morbidly Obese Women", DIABETES, vol. 54, May 2005 (2005-05-01), pages 1283 - 1288 *
KAHN ET AL.: "Perspectives in Diabetes: Islet Amyloid: A Long-Recognized but Underappreciated pathological Feature of Type 2 Diabetes", DIABETES, vol. 48, February 1999 (1999-02-01), pages 241 - 253, XP002979967, DOI: doi:10.2337/diabetes.48.2.241 *

Also Published As

Publication number Publication date
WO2007002830A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
EP3351558A3 (en) Material and methods for treating or preventing her-3 associated diseases
EA200801717A1 (en) LOCAL APPLICATION COMPOSITION FOR SKIN CARE, PRODUCT ON ITS BASIS AND METHOD OF TREATMENT
WO2006107947A3 (en) Hyperspectral imaging in diabetes and peripheral vascular disease
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2007095586A3 (en) Neuronal pain pathway modulators
WO2005055973A3 (en) Endoparasiticidal agents for topical application
BRPI0911203A2 (en) peptide or peptide derivative, pharmaceutical composition, use of a peptide or peptide derivative, methods for treating a patient having a deficiency and for preparing the peptide or peptide derivative.
EP2486924A3 (en) Drugs and uses
CL2007002619A1 (en) COMPOUNDS DERIVED FROM 3-AZA-BICICLO [4.1.0] HEPTANO; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DEPRESSION.
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2007131133A3 (en) Methods and compositions relating to zpa polypeptides
FR2919187B1 (en) USE OF YEAST SKIN FOR THE TREATMENT AND / OR PREVENTION OF HYPERINSULINEMIA.
CL2008001719A1 (en) Compounds derived from [1,10] -phenanthroline; preparation procedure; pharmaceutical composition; and use in the treatment of neurodegenerative or hematological diseases.
WO2006063009A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
WO2005082398A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2007002830A3 (en) Diagnosis of and protection from hyperinsulinemia and type ii diabetes
WO2007117572A3 (en) Optical coherence tomographic detection of cells and killing of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06785846

Country of ref document: EP

Kind code of ref document: A2